Dependence on a single core product
Substantially all revenue is generated by Heartflow FFRCT Analysis, making results sensitive to one offering.
- Scope
- FFRCT Analysis
- Materiality
- high
Heartflow, Inc.
Heartflow, Inc. develops software-based cardiovascular diagnostics that analyze coronary CT angiography (CCTA) images to help physicians assess coronary artery disease without invasive procedures. Its commercial platform is sold on a usage-driven basis, with core products including Heartflow FFRCT Analysis and Heartflow Plaque Analysis, and it is expanding into workflow tools such as Heartflow RoadMap and the planned PCI Planner.
−33,3 %
76,8 %
−66,3 %
+39,9 %
5.20
5.20
| % | |
|---|---|
| FFRCT Analysis | 98% AI-enabled coronary physiology analysis used to assess blood flow restriction from CCTA scans. |
| Plaque Analysis | 2% Coronary plaque assessment product used to support treatment decisions and risk stratification. |
| Workflow tools | 0% RoadMap and planned PCI Planner features that improve workflow efficiency and retention. |
Heartflow sells primarily to hospitals, health systems, and imaging centers that order analyses for patients being...
- Large health systemsprimary
Multi-facility systems that buy access across several accounts and drive meaningful case volume.
- Individual hospital and imaging accountsprimary
Facilities that order FFRCT and plaque analyses for routine CAD evaluation.
- Referring physicianssecondary
Cardiologists and other clinicians who choose Heartflow to avoid invasive testing and improve triage.
- Payors and reimbursement decision-makersprimary
Government and third-party payors whose coverage and payment policies determine adoption economics.
Heartflow’s commercial base is centered in the United States, where it had more than 1,100 accounts as of December 31,...
- •United States is the core market and main source of installed-base growth
- •International presence includes the UK, EU, Australia, Canada, and Japan
- •Small direct commercial teams support non-U.S. markets
- •No manufacturing footprint was disclosed; business is software and service based
- •Coverage and reimbursement vary by country and affect adoption speed
Heartflow is focused on expanding utilization within its installed base while adding new accounts through a scalable,...
01
Grow utilization at existing accountsshort-term
Revenue is usage-driven, so more cases per account directly increase sales.
02
Expand Plaque Analysis adoptionmedium-term
The product is a long-term growth driver but still early in commercialization.
03
Build a broader platform around workflow and PCI planningmedium-term
Adjacent tools can improve retention and make the platform more embedded in care pathways.
04
Scale international commercializationlong-term
Approved markets outside the U.S. provide additional growth without changing the core product.
Heartflow is highly exposed to reimbursement policy, physician adoption, and customer concentration because most...
Reimbursement and coverage risk
If payors do not cover the platform or reduce payment amounts, provider adoption can slow materially.
- Scope
- Government and third-party payors
- Materiality
- high
AI and model performance risk
Incorrect design, poor data, bugs, or cybersecurity issues could impair product performance and create liability.
- Scope
- AI algorithms and computational fluid dynamics models
- Materiality
- high
Customer concentration
A small number of large health systems can represent a disproportionate share of revenue.
- Scope
- Large health systems and multi-account customers
- Materiality
- medium
Plaque Analysis commercialization risk
The product is still nascent and may not achieve expected market acceptance or utilization.
- Scope
- New product adoption
- Materiality
- medium
Usage-based revenue recognition
Can create volatility in reported revenue and margins
Seasonality and utilization variability
Makes quarter-to-quarter comparisons less comparable
Capitalized software and contract fulfillment costs
Affects gross margin and operating leverage
Stock-based compensation
Impacts operating loss and non-cash expense profile
Debt conversion and repayment around IPO
Affects interest expense, leverage, and cash flow presentation
: 28.4.2026